Meeting
2019 ASCO Annual Meeting
Risk stratification in earl- stage luminal breast cancer patients treated with and without RT.
Authors
Charlotta Wadsten
Umea University, Department of Surgical and Perioperative Science, Umea, Sweden
Charlotta Wadsten , Pat W. Whitworth , Rakesh Patel , Jess Savala , Fredrik Warnberg , Troy Bremer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Citation
J Clin Oncol 37, 2019 (suppl; abstr 568)
DOI
10.1200/JCO.2019.37.15_suppl.568
Abstract #
568
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Changes in p16INK4a (p16) expression, a biomarker of aging, in peripheral blood T-cells (PBTC) in patients receiving anthracycline (A) vs non-anthracycline (NoA) chemotherapy (CRx) for early-stage breast cancer (EBC).
First Author: Shlomit Strulov Shachar
Poster
2011 ASCO Annual Meeting
The expression of GATA-3 and FOXA1 in breast cancer: The biomarkers of hormone sensitivity in luminal-type tumors.
First Author: Y. Hisamatsu
Poster
2022 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer.
First Author: Sara A. Hurvitz
Poster
2021 ASCO Annual Meeting
TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.
First Author: Sara A. Hurvitz